Lōkahi Therapeutics Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), has announced its first external client engagement under its AI asset-discovery platform, ai², with Innovate GBM—a nonprofit focused on glioblastoma treatments. The collaboration, announced on September 23, 2026, involves two ai² PIPELINE teams evaluating brain tumor therapeutic assets for potential licensing and development. Innovate GBM retains full autonomy over whether to proceed with any identified opportunities, reflecting a sponsor-led model that could expand beyond oncology into biotech and investment firms.
Lokahi’s AI Asset Discovery Secures First External Client in Oncology
Lōkahi Therapeutics’ AI-driven pipeline division partners with Innovate GBM to identify glioblastoma therapeutic assets for licensing, marking a shift toward external sponsorships.
LF
Lucas Ferreira · Deals & Startups Desk · 23 Sept 2026 · 21:48 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
LF
Written by
Lucas Ferreira
Deals & Startups Desk
Lucas covers M&A activity and startup funding rounds, tracking deal structures and valuations to explain what a transaction means for the companies and markets involved.
More from Lucas Ferreira →
